ST. LOUIS--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, supports the U.S. Food and Drug Administration’s Risk Evaluation and Mitigation Strategy (REMS) for an important class of pain medications. Today, the FDA sent letters to sponsors of long-acting and extended release opioid medications requiring a class-wide REMS. The FDA Amendments Act of 2007 gave the FDA the authority to require a REMS from manufacturers to ensure that the benefits of a drug product outweigh its risks.
